A Retrospective Cohort Study of Extended Dupilumab Dosing in Atopic Dermatitis: Assessing the Impact on Disease Severity and Understanding Characteristics Linked to Successful Dose Extension

IF 1.6 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2026-08-10 Epub Date: 2026-06-21 DOI:10.1111/ajd.70165

Jessica McClatchy, Vanessa Tran, Gayle Ross

引用次数: 0

Abstract

Dupilumab is effective for moderate-to-severe atopic dermatitis, but optimal long-term dosing is unclear. In this single-centre retrospective study, 49 patients underwent dose extension to 300 mg Q3W or 300 mg Q4W, with EASI scores remaining low and stable over 18 months. Patients extending for good disease control had higher EASI90 rates. The impact of age, disease severity and therapy duration remains uncertain.

查看原文本刊更多论文

特应性皮炎延长Dupilumab剂量的回顾性队列研究：评估对疾病严重程度的影响并了解与成功延长剂量相关的特征

Dupilumab对中重度特应性皮炎有效，但最佳长期剂量尚不清楚。在这项单中心回顾性研究中，49名患者接受了剂量延长至300 mg Q3W或300 mg Q4W的治疗，EASI评分在18个月内保持较低且稳定。病情控制良好的患者EASI90率较高。年龄、疾病严重程度和治疗时间的影响仍不确定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.